Pharmaceuticals, Inc. (NASDAQ: INFI) today reported updated data
from a Phase 1 monotherapy study of duvelisib (IPI-145), an inhibitor of phosphoinositide-3-kinase
(PI3K)-delta and PI3K-gamma , which showed activity among patients
with relapsed/refractory indolent non-Hodgkin lymphoma (iNHL), a fatal
type of blood cancer.
for Infinity Reports New Results from Phase 1 Study of Investigational Oncology Compound Duvelisib at the American Society of Hematology Annual Meeting investment picks